A numerical trend favoring birtamimab in the primary composite end point for the overall population was observed and was hypothesized to be driven by a treatment effect in the most advanced patients (Mayo stage IV).
← all excerpts
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
1
—
—